FLT3 and acute myeloid leukemia: However, early reports [99] and the RATIFY trial [100] demonstrated synergy between midostaurin and standard induction chemotherapy, leading to its FDA approval in 2017 as a first-line therapy for FLT3-ITD/TKD AML.